[Update in the management of persistent pulmonary hypertension of the newborn]

Rev Med Liege. 2007 May-Jun;62(5-6):284-7.
[Article in French]

Abstract

Persistent pulmonary hypertension of the newborn is a severe disease leading to persistent and refractory hypoxemia with bad outcomes. The introduction of inhaled nitric oxide therapy significantly improved short and long term prognosis of those infants. More recently, sildenafil also appeared promising, but regimen and indications still need to be delineated.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Administration, Inhalation
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Infant, Newborn
  • Nitric Oxide / administration & dosage*
  • Piperazines / therapeutic use*
  • Purines / therapeutic use
  • Sildenafil Citrate
  • Sulfones / therapeutic use*
  • Vasodilator Agents / therapeutic use*

Substances

  • Piperazines
  • Purines
  • Sulfones
  • Vasodilator Agents
  • Nitric Oxide
  • Sildenafil Citrate